Feel free to contact us directly or use our website to seamlessly request an appointment online and start feeling your absolute best today
These effects could be particularly valuable in treating conditions such as inflammatory bowel disease, where mucosal healing is a critical therapeutic endpoint
Conclusions Ultimately, the current maintenance dose of 1,000 mcg B12 every 3 months may confer long term harm, therefore it seems that once B12 levels are stabilised well within acceptable range, then the standard B12 intervention of 1000 mcg should be administered annually, and monitored with pre-injection annual testing of levels

Retatrutide vs tirzepatide vs semaglutide Category Receptor targets Retatrutide GLP-1 + GIP + Glucagon (triple) Tirzepatide GLP-1 + GIP (dual) Semaglutide GLP-1 only (single) Category Half-life Retatrutide ~6 days Tirzepatide ~5 days Semaglutide ~7 days Category Dose frequency Retatrutide Once weekly Tirzepatide Once weekly Semaglutide Once weekly Category Max studied dose Retatrutide 12 mg/week Tirzepatide 15 mg/week Semaglutide 2.4 mg/week Category Peak weight loss in trials Retatrutide -28.7% at 68 weeks (Phase 3 TRIUMPH-4) Tirzepatide -22.5% at 72 weeks (SURMOUNT-1) Semaglutide -15.8% at 68 weeks (STEP-1) Category FDA status (June 2026) Retatrutide Investigational, Phase 3 Tirzepatide Approved (obesity + T2D) Semaglutide Approved (obesity + T2D) Category Liver fat Retatrutide Up to 82% reduction (Phase 2 substudy) Tirzepatide Significant reduction Semaglutide Moderate reduction Category Unique angle Retatrutide Triple agonism may raise energy expenditure via glucagon pathway Tirzepatide Dual agonism balances effect and tolerability Semaglutide Longest clinical track record

The evidence is promising, showing B12s benefits across various conditions
This stability makes BPC-157 a viable, and perhaps even ideal, solution for a wide range of clinical practices that aim to provide the most effective digestive and musculoskeletal support to their patients